2-cyclopropyl-pent-3-yn-2-ol | 13701-05-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-cyclopropyl-pent-3-yn-2-ol
• 英文别名: 2-Cyclopropylpent-3-yn-2-ol
• CAS: 13701-05-8
• 化学式: C₈H₁₂O
• 分子量: 124.183
• InChiKey: QUMVOIUDZVCBDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-cyclopropyl-pent-3-yn-2-ol 在 lithium aluminium tetrahydride 作用下， 生成 (2E,4E)-7-acetoxy-4-methyl-hepta-2,4-diene
  参考文献：
  名称：

  透明质酸和等高线alcools多不饱和度obtenus par易位同位变体

  摘要：

  DOI：

  10.1016/s0040-4020(01)90953-6
• 作为产物：
  描述：

  环丙甲基酮 、 丙炔 生成 2-cyclopropyl-pent-3-yn-2-ol
  参考文献：
  名称：

  透明质酸和等高线alcools多不饱和度obtenus par易位同位变体

  摘要：

  DOI：

  10.1016/s0040-4020(01)90953-6

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2016123391A1

  公开（公告）日：2016-08-04

  The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.

  本发明涉及式(I)的化合物及其盐，其中R1-R6具有规范中定义的任何值，以及其组合物和用途。这些化合物可用作TAF1的抑制剂。还包括包含式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗各种TAF1介导的疾病中使用这些化合物和盐的方法。
• [EN] ANTIRETROVIRAL AGENTS<br/>[FR] AGENTS ANTIRÉTROVIRAUX
  申请人：GILEAD SCIENCES INC

  公开号：WO2016033243A9

  公开（公告）日：2016-05-19
• Cumulated Trienephosphine Oxides. Bimolecular Trapping of an Alkylidenecyclopropylidene
  作者：Christiane Santelli-Rouvier、Loïc Toupet、Maurice Santelli

  DOI：10.1021/jo970771u

  日期：1997.12.1

  Dihalocarbene addition to allenic phosphine oxides occurs mainly at the allylic double bond. Treatment of dibromocarbene adducts with BuLi leads to cumulated trienephosphine oxides. In some cases, the intermediate alkylidenecyclopropylidene (or its precursor) is exceptionally stabilized, and this carbene (or carbenoid) is trapped by the corresponding cumulated trienephosphine oxide in a bimolecular process. The resultant spiropentane is formed in a regio- and stereoselective manner.
• Sakharov, B. N.; Lipkin, M. A.; Markevich, V. S., Journal of Organic Chemistry USSR (English Translation), 1992, vol. 28, # 5.1, p. 714 - 717
  作者：Sakharov, B. N.、Lipkin, M. A.、Markevich, V. S.

  DOI：——

  日期：——
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：GENENTECH, INC.

  公开号：US20180009805A1

  公开（公告）日：2018-01-11

  The present invention relates to compounds of formula (I): and to salts thereof, wherein R 1 -R 6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.